

Takefumi Komiya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5498867/publications.pdf>

Version: 2024-02-01

26
papers

694
citations

1478505

6
h-index

677142

22
g-index

26
all docs

26
docs citations

26
times ranked

964
citing authors

#	ARTICLE	IF	CITATIONS
1	t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. <i>Nature Genetics</i> , 2003, 33, 208-213.	21.4	523
2	A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in <i>PTEN</i> . <i>Oncologist</i> , 2019, 24, 1510-e1265.	3.7	40
3	PD-L1 expression in small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 1853-1855.	2.8	32
4	Primary lung mucoepidermoid carcinoma: analysis of prognostic factors using surveillance, epidemiology and end results program. <i>Clinical Respiratory Journal</i> , 2017, 11, 847-853.	1.6	24
5	Advances in the Treatment of Mucoepidermoid Carcinoma. <i>World Journal of Oncology</i> , 2022, 13, 1-7.	1.5	11
6	Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database. <i>Radiotherapy and Oncology</i> , 2019, 131, 75-80.	0.6	9
7	<i>TP53</i> Gene and Cancer Resistance in Elephants. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1789.	7.4	8
8	Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Real-world data from 86,173 patients. <i>Thoracic Cancer</i> , 2021, 12, 2943-2948.	1.9	7
9	Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis. <i>Cancer Medicine</i> , 2021, 10, 923-932.	2.8	6
10	Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. <i>Translational Lung Cancer Research</i> , 2017, 6, 600-610.	2.8	5
11	Brain metastasis as exclusion criteria in clinical trials involving extensive-stage small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3099-3104.	2.5	5
12	Who treats lung cancer? Results from a global survey. <i>Respiratory Investigation</i> , 2017, 55, 308-313.	1.8	4
13	Overview of publications on lung cancer using the SEER database. <i>Respiratory Investigation</i> , 2018, 56, 424-426.	1.8	4
14	Difference of environment behind research and clinical practice between USA and Japan. <i>Journal of Thoracic Disease</i> , 2020, 12, 3804-3808.	1.4	3
15	Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 66-71.	1.9	2
16	Status of oncologic specialties: global survey of physicians treating cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 237-243.	2.2	2
17	NSCLC: State of the Art Diagnosis, Treatment, and Outcomes. <i>Current Pulmonology Reports</i> , 2018, 7, 29-41.	1.3	2
18	Recent trends in use of adjuvant chemotherapy in elderly stage II-III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1180-1186.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Role of thoracic radiation in extensive stage small cell lung cancer: a NCDB analysis. <i>Medical Oncology</i> , 2021, 38, 44.	2.5	2
20	Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 565-569.	1.9	1
21	Prognostic and Predictive Value of KRAS Mutation in NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, e128-e129.	1.1	1
22	Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer: A NCDB analysis. <i>Radiotherapy and Oncology</i> , 2020, 148, 8-13.	0.6	1
23	Who wins the race of predicting chemoradiation-induced esophagitis? Is there anyone else to join the competition? In response to Tang et al.. <i>Radiotherapy and Oncology</i> , 2014, 113, 298-299.	0.6	0
24	In response to Hsia TC et al. "Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database". <i>Radiotherapy and Oncology</i> , 2019, 135, 200.	0.6	0
25	Ethnic difference in chemoradiation-induced esophagitis in unresectable stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e18518-e18518.	1.6	0
26	An Overview of Lung and Breast Cancer Using the National Cancer Database. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 163-167.	1.2	0